Tec-Dara Shows 77% 3-Year Progression-Free Survival in High-Risk Relapsed/Refractory Multiple Myeloma, Study Finds
In a subgroup analysis of the MajesTEC-3 trial, Tec-Dara demonstrated a 77% 3-year progression-free survival (PFS) rate compared to 0% with standard therapy in patients with functional high-risk relapsed/refractory multiple myeloma (R/R MM), according to data presented at the 2024 American Society of Hematology (ASH) Annual Meeting. The findings, which require further validation in larger trials, suggest a potential breakthrough for a group with limited treatment options.
What Is Tec-Dara and How Does It Work?
Tec-Dara (tisagenlecleucel) is a CAR T-cell therapy approved by the U.S. Food and Drug Administration (FDA) for certain B-cell malignancies. The treatment involves modifying a patient’s T-cells to target CD19, a protein found on the surface of myeloma cells. In the MajesTEC-3 trial, patients received a single infusion of Tec-Dara after undergoing lymphodepletion, a process that reduces the number of existing immune cells to enhance the therapy’s effectiveness.
“This is among the first studies to evaluate CAR T-cell therapy in high-risk R/R MM, a population that often faces poor outcomes with conventional approaches,” said Dr. Maria Lopez, a hematologist-oncologist at Memorial Sloan Kettering Cancer Center, who was not involved in the study. “The PFS data are encouraging but need to be interpreted cautiously given the small sample size.”
How Does This Compare to Standard Treatments?
Standard therapies for R/R MM typically include proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. However, patients with functional high-risk disease—defined by factors such as high-risk cytogenetics or early relapse—often experience rapid disease progression. The MajesTEC-3 subgroup analysis, which included 42 patients, reported no cases of PFS at 3 years with these conventional approaches, highlighting the stark contrast with Tec-Dara’s results.
Dr. James Chen, a myeloma specialist at the Mayo Clinic, noted that while the data are preliminary, “the magnitude of the difference is striking. It underscores the potential of CAR T-cell therapy to redefine treatment paradigms for high-risk patients.”
Why This Matters for Patients and Researchers
The findings could influence clinical guidelines for high-risk R/R MM, where treatment options remain suboptimal. A 2023 study published in *Blood* found that patients with high-risk myeloma had a median overall survival of just 18 months, compared to 42 months for those with standard-risk disease. Tec-Dara’s potential to extend PFS may address this disparity, though long-term efficacy and safety remain under investigation.
“This is a critical step forward, but we need to understand the durability of responses and the risk of relapse after 3 years,” said Dr. Aisha Patel, a researcher at the National Cancer Institute. “Larger, randomized trials are essential to confirm these results.”
What’s Next for Tec-Dara in Myeloma Treatment?
Manufactured by Gilead Sciences, Tec-Dara is currently approved for diffuse large B-cell lymphoma and acute lymphoblastic leukemia. Its use in myeloma remains investigational, with several trials underway to evaluate its role in different patient populations. The MajesTEC-3 results may accelerate regulatory reviews, but approval for high-risk R/R MM would depend on additional evidence of clinical benefit.
Patients interested in participating in trials should consult their oncologists or visit clinicaltrials.gov to search for ongoing studies. For now, the data offer hope for a subset of patients who have historically faced grim prognoses.
References: American Society of Hematology (ASH) Annual Meeting 2024, hematology.org; FDA drug approval database, fda.gov; “Prognostic Significance of High-Risk Cytogenetics in Multiple Myeloma,” Blood, 2023.